Bezlotoxumab

Kathryn Dzintars, Pharm.D., BCPS
Bezlotoxumab is a topic covered in the Johns Hopkins ABX Guide.

To view the entire topic, please or .

Pediatrics Central™ is an all-in-one application that puts valuable medical information, via your mobile device or the web, in the hands of clinicians treating infants, children, and adolescents. Explore these free sample topics:

-- The first section of this topic is shown below --

INDICATIONS

FDA

Reduce the recurrence of Clostridium difficile infections (CDIs) in patients 18 years of age and older who are receiving antibacterial CDI drug treatment and are at high risk for CDI recurrence.

-- To view the remaining sections of this topic, please or --

INDICATIONS

FDA

Reduce the recurrence of Clostridium difficile infections (CDIs) in patients 18 years of age and older who are receiving antibacterial CDI drug treatment and are at high risk for CDI recurrence.

There's more to see -- the rest of this entry is available only to subscribers.

Last updated: March 4, 2018